Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.63 |
| ▸ | NOS1 | P29475 | 3/20 | 0.63 |
| ▸ | NOS2 | P35228 | 3/20 | 0.63 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 8/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29615484 | 1.00 | NOS3 (0.63) | NOS3NOS1NOS2DYRK1AMAOA | |
| SCHEMBL15689737 | 0.83 | NOS3 (0.60) | NOS3NOS1NOS2DYRK1AKDM4E | |
| SCHEMBL4555865 | 0.82 | NCF1 (0.59) | NOS3NOS1NOS2DYRK1AKDM4E | |
| SCHEMBL25595272 | 0.81 | NOS3 (0.58) | NOS3NOS1NOS2DYRK1AKDM4E | |
| SCHEMBL21999454 | 0.81 | NOS3 (0.57) | NOS3NOS1NOS2DYRK1AKDM4E | |
| SCHEMBL15223391 | 0.81 | CCR1 (0.61) | NOS3NOS1NOS2DYRK1AMAOA | |
| SCHEMBL24127361 | 0.79 | DYRK1A (0.49) | NOS3NOS1NOS2DYRK1AMAOA | |
| SCHEMBL27904580 | 0.79 | NOS3 (0.55) | NOS3NOS1NOS2DYRK1AKDM4E | |
| SCHEMBL19950985 | 0.79 | NOS3 (0.55) | NOS3NOS1NOS2DYRK1AMAOA | |
| SCHEMBL25877903 | 0.79 | DYRK1A (0.49) | NOS3NOS1NOS2DYRK1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021013864-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL) -PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2021-01-28 | — | — | WO | disclosed |
| US-10669269-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-9938261-B2 | Heterocyclic compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2018-04-10 | — | — | US | disclosed |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-9809590-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| EP-2766359-B9 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS MODULATORS OF TYPE III RECEPTOR TYROSINE KINASES | AMBIT BIOSCIENCES CORP (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-3136461-A1 | PHOTOELECTRIC CONVERSION ELEMENT, SOLAR CELL IN WHICH SAME IS USED, AND METHOD FOR MANUFACTURING PHOTOELECTRIC CONVERSION ELEMENT | Fujifilm Corporation (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20160362405-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2016-12-15 | — | — | US | disclosed |
| US-9452167-B2 | Heterocyclic compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-09-27 | — | — | US | disclosed |
| CN-105924437-A | Compounds As Type III Receptor Tyrosine Kinase Inhibitors | 阵列生物制药公司 | 2016-09-07 | — | — | CN | disclosed |
| WO-2011079076-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2010039825-A2 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| CN-101679423-A | Imidazo [1, 2-a ] pyridine compounds as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC | 2010-03-24 | — | — | CN | disclosed |
| CN-101679422-A | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC | 2010-03-24 | — | — | CN | disclosed |
| US-20100029633-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-02-04 | — | — | US | disclosed |
| EP-2139888-A2 | IMIDAZOÝ1,2-A¨PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-2137184-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008124323-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008121687-A2 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029633-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | PIM1, PIM3, PIM2 | NOS3 1033/4885NOS1 870/4885NOS2 1420/4885 |
| US-20160362405-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | FLT3, PDGFRB, PDGFRA | NOS3 1515/4885NOS1 1734/4885NOS2 1492/4885 |
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | PIM1, PIM3, PIM2 | NOS3 1274/4885NOS1 1013/4885NOS2 1621/4885 |
| US-10669269-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | MUSK, FGFR1, PDGFRA | NOS3 564/4885NOS1 1204/4885NOS2 1317/4885 |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | LTK, MUSK, FGFR1 | NOS3 778/4885NOS1 1915/4885NOS2 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.